Literature DB >> 2542300

Platelet-derived growth factor receptor inducibility is acquired immediately after translation and does not require glycosylation.

M T Keating1, C C Harryman, L T Williams.   

Abstract

Antibodies to phosphotyrosine were used in immunoprecipitation experiments to determine if post-translational modification of the platelet-derived growth factor (PDGF) receptor was required for the acquisition of ligand-induced tyrosine kinase activity. In intact Balb/c 3T3 fibroblasts, only the fully processed 180-kDa receptor was activated (tyrosine-phosphorylated) by PDGF. In a cell-free assay, however, the tyrosine-phosphorylated forms of the 160- and 145-kDa PDGF receptor precursors were also detected. These activated precursors were immunoprecipitated after brief (5-15 min) metabolic labeling periods. Thus the receptor could bind PDGF and induce tyrosine kinase activity shortly after translation. Unlike the mature form of the receptor, the 160-kDa receptor precursor was resistant to digestion with endo-alpha-N-acetylgalactosaminidase and thus did not contain O-linked oligosaccharides. Since this receptor precursor was activated by PDGF in the cell-free assay, the addition of O-linked sugars must not be necessary for ligand binding activity. Incubation of cells with tunicamycin completely inhibited N-linked glycosylation of the PDGF receptor. Nevertheless, PDGF still induced tyrosine phosphorylation of the 130-kDa aglycoreceptor in lysates of tunicamycin-treated cells. Thus, the addition of N-linked oligosaccharides was also not required for receptor activation. These findings show that the PDGF receptor acquired the ability to be activated by ligand cotranslationally or immediately after translation and that the addition of N- or O-linked oligosaccharides was not required for ligand binding and tyrosine kinase activities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542300

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Direct activation of phospholipase C-gamma by fibroblast growth factor receptor is not required for mesoderm induction in Xenopus animal caps.

Authors:  A J Muslin; K G Peters; L T Williams
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

2.  Differences in the glycosylation of rat submandibular kallikreins.

Authors:  X S Zhang; G B Proctor; J R Garrett; D K Shori; G H Carpenter
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

3.  Human microvascular endothelial cells express receptors for platelet-derived growth factor.

Authors:  J G Beitz; I S Kim; P Calabresi; A R Frackelton
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

Review 4.  Role of N-glycans in growth factor signaling.

Authors:  Motoko Takahashi; Takeo Tsuda; Yoshitaka Ikeda; Koichi Honke; Naoyuki Taniguchi
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

5.  PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.

Authors:  F A Arts; D Chand; C Pecquet; A I Velghe; S Constantinescu; B Hallberg; J-B Demoulin
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

6.  Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.

Authors:  Aleksander Hinek; Tetyana D Bodnaruk; Severa Bunda; Yanting Wang; Kela Liu
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

7.  Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.

Authors:  Cinzia Lanzi; Enrica Favini; Laura Dal Bo; Monica Tortoreto; Noemi Arrighetti; Nadia Zaffaroni; Giuliana Cassinelli
Journal:  J Exp Clin Cancer Res       Date:  2021-12-02

8.  A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.

Authors:  Dinel Pond; Florence A Arts; Nancy J Mendelsohn; Jean-Baptiste Demoulin; Gunter Scharer; Yoav Messinger
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

9.  Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.

Authors:  Carman K M Ip; Patrick K S Ng; Kang Jin Jeong; S H Shao; Zhenlin Ju; P G Leonard; Xu Hua; Christopher P Vellano; Richard Woessner; Nidhi Sahni; Kenneth L Scott; Gordon B Mills
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.